| oxaliplatin / Generic mfg. |
NCT05882396: Rood's Approach and Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients |
|
|
| Not yet recruiting | N/A | 60 | NA | Rood's approach, Traditional physical therapy program | Cairo University | Colorectal Cancer, Peripheral Neuropathy | 12/23 | 01/24 | | |
NACSOC, NCT02972541: Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer |
|
|
| Recruiting | N/A | 248 | RoW | Stenting with neoadjuvant chemotherapy, Stenting with immediate Surgery | Beijing Chao Yang Hospital | Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction | 12/23 | 12/23 | | |
NACSOC-02, NCT05202314: Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer |
|
|
| Recruiting | N/A | 20 | RoW | Immunotherapy (Camrelizumab), Chemotheray (CAPOX or mFOLFOX6) | Beijing Chao Yang Hospital | Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction, Immunotherapy | 12/23 | 12/26 | | |
NCT04047953: Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma |
|
|
| Recruiting | N/A | 95 | RoW | Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1, Paclitaxel (albumin-bound) + Oxaliplatin + S-1, Nab-paclitaxel + Oxaliplatin + S-1 | Peking University Cancer Hospital & Institute | Gastric Adenocarcinoma | 12/23 | 11/26 | | |
ChiCTR2100045399: TCM evidence-based capacity building and evidence-based implementation plan of TCM combined with chemotherapy in treatment of metastatic colorectal cancer:A bidirectional cohort study of Zhenqiliujun anti-cancer granules combined with mFOLFOX6/FOLFIRI regimen and bevacizumab/cetuximab in first-line treatment of advanced metastatic colorectal |
|
|
| Recruiting | N/A | 362 | | MFOLFOX6 /FOLFIRI regimen + bevacizumab/cetuximab + Zhenqi Liujun cancer suppressant granules. ;MFOLFOX6 /FOLFIRI + bevacizumab/cetuximab | Department of Oncology, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University; The Traditional Chinese Medicine Hospital Affiliated to Southwest, National Administration ofnTraditional Chinese Medicine | colorectal cancer | | | | |
| Recruiting | N/A | 100 | RoW | Endoscopic treatment, TIPS | Shanghai Zhongshan Hospital, First Affiliated Hospital of Wenzhou Medical University, Shanghai Minhang Central Hospital, Anhui Provincial Hospital | Gastroesophageal Varices Hemorrhage, Gastrointestinal Cancer, Received Oxaliplatin-based Chemotherapy | 12/23 | 12/23 | | |
ChiCTR2100054728: A randomized, controlled, double-blind, multicenter clinical study of Huangqi Guizhi Wuwu Tang granules for the treatment of peripheral neurotoxicity induced by oxaliplatin in colorectal cancer chemotherapy |
|
|
| Not yet recruiting | N/A | 144 | | Subjects were given Huangqi Gui Zhi Wu Wu Wu Tang granules twice a day, once in the morning and once in the evening, one sachet each time, with warm water ;Subjects were given a simulated dose of 1 sachet twice a day, once in the morning and once in the evening, with warm water. | Jiangsu Institute of Traditional Chinese Medicine; Jiangsu Institute of Traditional Chinese Medicine, Jiangsu Provincial Department of Science and Technology, Jiangsu Province Key R&D Program (Social Development) Project | Peripheral neurotoxicity caused by oxaliplatin for colorectal cancer chemotherapy | | | | |
NCT06194981: Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage |
|
|
| Recruiting | N/A | 260 | RoW | Oxaliplatin and capecitabine/ S-1 and capecitabine, Xeloda | The First Affiliated Hospital of Zhengzhou University | Gastric Cancer | 03/24 | 05/24 | | |
NCT05215665: GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma |
|
|
| Recruiting | N/A | 120 | RoW | GEMOX Regimen, Lenvatinib, Toripalimab | Tianjin Medical University Cancer Institute and Hospital | Cholangiocarcinoma | 01/24 | 01/26 | | |
PDAC-LIV, NCT06349278: Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX |
|
|
| Recruiting | N/A | 15 | Canada | Pancreatic resection and non-anatomic liver resections. | Laval University | Pancreas Adenocarcinoma, Pancreas Metastases, Pancreas Cancer | 01/26 | 01/29 | | |
SALVLIV, NCT06199232: Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment |
|
|
| Recruiting | N/A | 47 | RoW | HAIC+targeted therapy+PD-1 inhibitor, HAIC+Fruquintinib/Cetuximab+Tislelizumab | Peking University | Liver Metastasis Colon Cancer, ctDNA Genotype, MSS, Failed From Standard Treatment | 01/26 | 01/27 | | |
PACsign, NCT05475366: Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures |
|
|
| Recruiting | N/A | 62 | Europe | Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies) | Institut Curie | Carcinoma, Pancreatic Ductal, Prognosis | 12/26 | 12/26 | | |
NCT05800080: An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC |
|
|
| Not yet recruiting | N/A | 114 | RoW | Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, Teggio, Oxaliplatin | Xijing Hospital | Gastric Cancer | 02/24 | 02/25 | | |
UNLACC, NCT06244537: Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer |
|
|
| Not yet recruiting | N/A | 20 | NA | MR-linac | Sichuan Cancer Hospital and Research Institute | Safety and Efficacy | 06/25 | 12/25 | | |
NCT03958747: Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy |
|
|
| Recruiting | N/A | 20 | US | Ultrasound - Serial and Tibial Nerve, Skin Biopsy, Abbreviated Neurologic Exam, Blood draw, Nerve Conduction Study, QLQ-CIPN20 Questionnaire Administration | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Gastrointestinal Cancer, Colorectal Cancer | 10/24 | 10/24 | | |
NCT05715632: New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX |
|
|
| Recruiting | N/A | 46 | RoW | Carrelizumab combined with XELOX | Tang-Du Hospital | Gastric Cancer | 03/24 | 03/25 | | |
NCT06349044: A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. |
|
|
| Recruiting | N/A | 150 | RoW | Hypofractionated radiotherapy/SBRT（5-8 Gy/fx，3-5 fx）, Anti-PD-1 monoclonal antibody, Oxaliplatin and Capecitabine, Anti-VEGF 15mg/kg, Anti-VEGF 7.5mg/kg, Gemcitabine and Cisplatin, Gemcitabine and Albumin paclitaxel | Zhejiang Cancer Hospital | Gastroesophageal Junction Adenocarcinoma, Liver Cancer Stage IV, Biliary Tract Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Gastric Cancer | 12/25 | 12/25 | | |
SMART, NCT04276857: Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer |
|
|
| Not yet recruiting | N/A | 27 | NA | Irreversible electroporation (NanoKnife® ), FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) or gemcitabine/nab-paclitaxel | University of Saskatchewan | Locally Advanced Pancreatic Cancer, Irreversible Electroporation | 03/26 | 03/26 | | |
CCHOWW, NCT05000697: Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait |
|
|
| Recruiting | N/A | 216 | RoW | Oxaliplatin, 5FU + Oxaliplatin, 5FU | Hospital Alemão Oswaldo Cruz | Rectal Cancer, Consolidation | 04/24 | 04/27 | | |
NCT06335147: PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer |
|
|
| Not yet recruiting | N/A | 23 | NA | Serplulimab, mFOLFOX6, HLX10 | Henan Cancer Hospital | Metastatic Colon Cancer | 01/26 | 01/26 | | |
cmPAT, NCT06167967: Circulating Tumor DNA Methylation Guiding Postoperative Adjuvant Chemotherapy in Stage III Colorectal Cancer |
|
|
| Recruiting | N/A | 990 | RoW | ctDNA methylation, standard treatment | Sir Run Run Shaw Hospital | Colorectal Cancer | 12/26 | 12/29 | | |
ChiCTR1900024092: A prospective, randomized, controlled, multicenter, phase III study of apatinib plus concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction |
|
|
| Recruiting | N/A | 180 | | Preoperative: Apatinib 250mg q.d. p.o. q4w; XELOX: Capecitabine 1000mg/m2 b.i.d. d1-14, Oxaliplatin 130 mg/m2 i.v.gtt. d1 q3w; Radiotherapy 45Gy/25f (1.8Gy/f/d, 5 f/w) Postoperative: Capecitabine 1000mg/m2 b.i.d. d1-14 q3w 2 cycles. ;Preoperative: XELOX: Capecitabine 1000mg/m2 b.i.d. d1-14, Oxaliplatin 130 mg/m2 i.v.gtt. d1 q3w, Radiotherapy: 45Gy/25f (1.8Gy/f/d，5 f/w); Postoperative: Capecitabine 1000mg/m2 b.i.d. d1-14 q3w 6 cycles. | Fourth Hospital of Hebei Medical University; the Fourth Hospital of Hebei Medical University, self-pay | gastroesophageal junction adenocarcinoma | | | | |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
ChiCTR2100043312: Efficacy and safety of PD1 inhibitor or (and) DNA methylation inhibitor combined with chemotherapy in the treatment of stage III / IV gastric / gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | N/A | 80 | | Sindilimab + Decitabine + XELOX ;Sindilimab + XELOX ;Decitabine + XELOX ;XELOX | Changzhi People's Hospital; Changzhi people's Hospital, Scientific Research Project of Shanxi Provincial Health Committee | Gastric cancer | | | | |
ChiCTR2300070449: A multicenter retrospective clinical study on the risk factors of oxaliplatin peripheral neurotoxicity and prognosis |
|
|
| Not yet recruiting | N/A | 500 | | none | Jiangsu Province Hospital on Integration of Chinese and Western Medicine; Jiangsu Province Hospital on Integration of Chinese and Western Medicine, none | Oxaliplatin-induced peripheral neuropathy | | | | |
NCT06313554: Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Not yet recruiting | N/A | 63 | NA | Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin | Fudan University | Intrahepatic Cholangiocarcinoma | 05/24 | 05/27 | | |
ChiCTR2100044579: A trial for construction of organoids database and individual drug sensitivity test of patients with cholangiocarcinoma (intrahepatic and extrahepatic cholangiocarcinoma) |
|
|
| Recruiting | N/A | 120 | | Treating with Gemcitabine and Cis-platinum ;Treating with Oxaliplatin and Fluorouracil ;Treating with Gemcitabine and Fluorouracil ;Treating with Gemcitabine ;Treating with Fluorouracil ;Treating with Oxaliplatin | Renji Hospital affiliated to Shanghai Jiaotong University, School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University, School of Medicine, Self financing by researchers | cholangiocarcinoma | | | | |
ChiCTR2100049451: Carrelizumab combined with XELOX in the treatment of stage IIIB/IIIC gastric cancer and gastroesophageal junction adenocarcinoma after D2 radical resection: a phase II clinical single-center, exploratory study |
|
|
| Not yet recruiting | N/A | 20 | | carrelizumab | Affilicated Huai'an First people's hospital of Nanjing Medical University; Affilicated Huai'an First people's hospital of Nanjing Medical University, Part at own expense | Gastric cancer | | | | |
NCT05426824: The Whole-course Management of Pegaspargase in ENKTL |
|
|
| Not yet recruiting | N/A | 72 | RoW | Pegaspargase（P-GOD）, Pegaspargase（PEMD） | The First Affiliated Hospital with Nanjing Medical University | Extranodal NK/T Cell Lymphoma | 07/24 | 07/25 | | |
NCT06443307: Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan |
|
|
| Recruiting | N/A | 933 | RoW | Irinotecan Liposome | Peking University | Colorectal Cancer, Solid Tumor | 07/26 | 08/26 | | |
NCT05030493: An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer |
|
|
| Recruiting | N/A | 757 | Japan | mFOLFOX6 + panitumumab combination therapy, mFOLFOX6 + bevacizumab combination therapy | Takeda | Colorectal Cancer | 07/24 | 07/24 | | |
| Not yet recruiting | N/A | 40 | US | Cryotherapy Gloves | NYU Langone Health | Colon Cancer, Peripheral Neuropathy | 10/25 | 12/25 | | |
NCT01595321: Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas |
|
|
| Active, not recruiting | N/A | 19 | US | Cyclophosphamide, Cytoxan, PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine, Pancreatic cancer vaccine, Stereotactic Body Radiation (SBRT), FOLFIRINOX, Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Skip Viragh Foundation | Pancreatic Cancer | 09/24 | 09/24 | | |
NCT05424692: Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer |
|
|
| Recruiting | N/A | 200 | RoW | 5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate, PTC drug sensitivity results | Peking Union Medical College Hospital | Colon Cancer, Rectal Cancer, Chemotherapy Effect, PTC, Exon Mutation | 09/24 | 09/26 | | |
NCT06061276: bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC |
|
|
| Recruiting | N/A | 40 | RoW | bTAE-HAIC, Lenvatinib, TKI inhibits, Camrelizumab, programmed cell death protein-1 (PD-1) antibody | Sun Yat-sen University | Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab, Lenvatinib | 06/25 | 12/25 | | |
ChiCTR2000035493: A randomized controlled trial for comparing XELOX versus ARTA+XELOX in the treatment of hepatocelullar carcinoma with recurrence after liver transplantation |
|
|
| Not yet recruiting | N/A | 109 | | ATRA+XELOX ;Placebo+XELOX | Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Self-financing | hepatocelullar carcinoma | | | | |
NCT05279612: Effect Analysis of Neoadjuvant Chemoradiotherapy Combined With Surgery in Laparoscope for Advanced Colon Cancer |
|
|
| Active, not recruiting | N/A | 177 | RoW | Short-term neoadjuvant chemoradiotherapy | Tang-Du Hospital | Colon Neoplasm | 10/24 | 05/25 | | |
NCT06035133: Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy |
|
|
| Not yet recruiting | N/A | 213 | NA | CapeOX + cetuximab, CapeOX + bevacizumab, radiotherapy | Tang-Du Hospital | Rectal Cancer | 11/24 | 11/27 | | |
| Recruiting | N/A | 120 | Europe | Fish oil, Corn oil | Vejle Hospital | Peripheral Neuropathy, Colorectal Cancer | 12/24 | 12/26 | | |
ChiCTR2200059750: A single-arm, prospective clinical study of neoadjuvant chemotherapy with trifluridine tipiracil (TAS-102) combined with oxaliplatin in locally advanced gastric carcinoma with different molecular subtypes |
|
|
| Not yet recruiting | N/A | 50 | | trifluridine tipiracil (TAS-102) combined with oxaliplatin | Fujian Tumor Hospital ; Fujian Tumor Hospital, Department of Gastrointestinal Oncology, Fujian Tumor Hospital | gastric carcinoma | | | | |
NCT06055179: XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial) |
|
|
| Recruiting | N/A | 98 | RoW | Xiao Chai Hu Tang (XCHT), Xiao Chai Hu Tang granules from Nin Jiom Medicine Manufactory (Hong Kong) Ltd, Placebo, Placebo provided by Nin Jiom Medicine Manufactory (Hong Kong) Ltd, Irinotecan regimen, Raloxifene | Guangzhou University of Traditional Chinese Medicine, University of Houston | Xiao Chai Hu Tang, Irinotecan-induced Diarrhea | 12/24 | 02/25 | | |
NCT05362825: Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer |
|
|
| Recruiting | N/A | 89 | RoW | Neo-adjuvant Chemotherapy FOLFOXIRI Regimen, synchronous resection surgery, Liver-first surgery, Primary/Bowel-first Surgery, No surgery | Cho Ray Hospital, University of Medicine and Pharmacy at Ho Chi Minh City | Liver Metastasis Colon Cancer, Synchronous Neoplasm | 12/24 | 01/25 | | |
ChiCTR2200066827: Study on the efficacy of MRI-guided short-course radiotherapy followed by chemotherapy for locally advanced rectal cancer |
|
|
| Recruiting | N/A | 30 | | Radiation Therapy + mFOLFOX6 regimen | Radiation Therapy Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China; Radiation Therapy Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, NO | Rectal Cancer | | | | |
CANWATCH, NCT03748485: Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis |
|
|
| Recruiting | N/A | 650 | RoW | wait and watch, adjuvant chemotherapy, mFOLFOX6 | Sixth Affiliated Hospital, Sun Yat-sen University | Colorectal Cancer, Adjuvant Chemotherapy | 12/25 | 12/27 | | |
NCT03253107: Predicting Biomarker of Gastric Cancer Chemotherapy Response |
|
|
| Recruiting | N/A | 800 | RoW | Chemotherapy, XP or Xelox +/- Herceptin | Kyungpook National University Hospital | Gastric Cancer, Chemotherapy Effect, Predictive Cancer Model | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 63 | US | Radiation therapy, FOLFOX regimen, Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire, Rectal biopsy samples, Blood for ctDNA | Washington University School of Medicine | Adenocarcinoma of the Lower Rectum | 09/24 | 04/26 | | |
ProphyPIPAC, NCT06091683: Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy to Prevent Colorectal Peritoneal Metastases |
|
|
| Recruiting | N/A | 10 | Europe | Pressurized intraperitoneal aerosol chemotherapy (PIPAC) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Peritoneal Metastases From Colorectal Cancer | 12/24 | 12/25 | | |
ChiCTR2200058645: Clinical study of organoid models for gastric cancer to predict neoadjuvant treatment outcomes |
|
|
| Not yet recruiting | N/A | 81 | | SOx ;XELOX | The First Affiliated Hospital of Naval Medical University; The First Affiliated Hospital of Naval Medical University, Shanghai Municipal Science and Technology Commission | gastric cancer | | | | |
ChiCTR2200060634: A two-arm, multicenter exploratory clinical study of anrotinib combined with piemprizumab and crapy in first-line treatment hemotheof metastatic colorectal cancer |
|
|
| Not yet recruiting | N/A | 30 | | Sequential therapy with arotinib, oxaliplatin, capecitabine, and paclitaxel ;Simultaneous treatment with arotinib + oxaliplatin + capecitabine + paiampilizumab | The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Chia Tai Tianqing Pharmaceutical Group Co. LTD | Colorectal cancer | | | | |
NCT05601323: A Study of Suizenji in Patients With Unresectable Pancreatic Cancer |
|
|
| Recruiting | N/A | 90 | Japan | Suizenji, Nal-IRI/FL, mFOLFIRINOX, Gem/nab-PTX | SONIRE Therapeutics Inc. | Unresectable Pancreatic Cancer | 10/25 | 10/25 | | |
ChiCTR2300069012: A single-arm clinical study to evaluate the safety, tolerability and pharmacokinetics of XELOX regimen combined with paclitaxel cationic liposomes administered via catheter artery perfusion in first-line treatment of patients with liver metastases |
|
|
| Not yet recruiting | N/A | 25 | | Taxol cationic liposomes for injection, oxaliplatin, capecitabine | Lishui Central Hospital of Zhejiang Province; Lishui Central Hospital of Zhejiang Province, Shiyao Group Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Liver metastasis | | | | |
ChiCTR2300070295: Effect of Guasha therapy on oxaliplatin-induced peripheral neuropathy |
|
|
| Not yet recruiting | N/A | 144 | | Guasha therapy, once a week for 4 weeks ;health education | Guangdong Provincial Hospital of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Administration of Traditional Chinese Medicine | Gastrointestinal cancer | | | | |
NCT05798884: Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients |
|
|
| Not yet recruiting | N/A | 150 | RoW | Acupuncture, Sham-acupuncture | Hong Kong Baptist University, Princess Margaret Hospital, Hong Kong, Queen Mary Hospital, Hong Kong | Colorectal Cancer, Oxaliplatin, Electro-acupuncture, Neurotoxicity | 01/25 | 04/25 | | |
NCT05832398: Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer |
|
|
| Recruiting | N/A | 186 | RoW | FOLFOX , FOLFIRI or FOLFOXIRI regimens, oxaliplatin, irinotecan, 5-fluorouracil, FOLFOX or CapeOX regimens, oxaliplatin, 5-fluorouracil | Nanfang Hospital, Southern Medical University, Sixth Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen University | Colorectal Cancer | 01/25 | 12/25 | | |
NCT05877573: Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer |
|
|
| Recruiting | N/A | 53 | RoW | Toripalimab, short-term radiotherapy, shor-course radiotherapy, Oxaliplatin, Capecitabine | Nanfang Hospital, Southern Medical University, Shanghai Junshi Bioscience Co., Ltd. | Locally Advanced, High-Risk, Rectal Cancer, MSS | 01/25 | 08/26 | | |
NCT06070636: bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 30 | RoW | bTAE-HAIC, Lenvatinib, TKI inhibits, Sintilimab, programmed cell death protein-1 (PD-1) antibody | Sun Yat-sen University | Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Lenvatinib, Sintilimab | 01/25 | 06/25 | | |
PeRFormanCe, NCT05298722: Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy ( Trial) |
|
|
| Recruiting | N/A | 45 | Europe | Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires., Analysis of imaging with radiomics and genetic analysis of peripheral blood samples (liquid biopsy) | University Hospital, Ghent | Pancreatic Cancer | 03/25 | 03/26 | | |
ChiCTR2300070126: Clinical application of superstable homogeneous mixture lipiodol-oxaliplatin pure drug mixture TACE therapy combined with immunotherapy in improving the therapeutic effect of unresectable hepatocellular carcinoma |
|
|
| Not yet recruiting | N/A | 50 | | Innovative physical method mixed lipiodol-platinum drugs combined with immunotherapy ;traditional interventional surgery | Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Southwest Medical University, optional items | Advanced unresectable hepatocellular carcinoma | | | | |
NCT06464601: A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer |
|
|
| Not yet recruiting | N/A | 70 | RoW | fruquintinib combined with immune checkpoint inhibitors and chemotherapy | Wuhan University | Gastric Cancer | 03/26 | 03/27 | | |
| Active, not recruiting | N/A | 56 | US | Best Practice, standard of care, standard therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Repetitive Transcranial Magnetic Stimulation, rTMS, Sham Intervention | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Malignant Neoplasm, Neuropathy | 04/25 | 04/25 | | |
ChiCTR2200065759: A Clinical Trial on Constructing a Treatment Mode of Integrated Traditional Chinese and Western Medicine in the Treatment of Metastatic Colorectal Cancer Basing on the ''Spleen-Kidney Deficiency'' Pathogenesis Theory |
|
|
| Not yet recruiting | N/A | 98 | | Tiao Pi An Chang Fang+XELOX（CapeOX）/mFOLFOX6 ;Placebo+XELOX（CapeOX）/mFOLFOX6 | China-Japan Friendship Hospital; China-Japan Friendship Hospital, China-Japan Friendship Hospital High-level hospital clinical business funds special clinical research project | Colorectal Cancer (CRC) | | | | |
NCT06470178: A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents |
|
|
| Not yet recruiting | N/A | 70 | RoW | corhot1: chemotherapy combined with fruquintinib, corhot2: chemotherapy combined with fruquintinib | Wuhan University | Colorectal Cancer | 04/26 | 04/27 | | |
ChiCTR2300071748: Dynamic changes of body composition and toxic side effects in patients with gastric cancer treated with SOX/XELOX chemotherapy under the background of active nutritional intervention |
|
|
| Not yet recruiting | N/A | 50 | | Active nutritional intervention | Ordos Central Hospital, Inner mongolia; Ordos Central Hospital, Inner Mongolia, Construction of key disciplines | Gastric cancer | | | | |
NCT05731336: A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan. |
|
|
| Recruiting | N/A | 500 | RoW | | Sun Yat-sen University | Advanced Colorectal Cancer | 05/25 | 05/26 | | |
ChiCTR2200061347: A single-center, prospective, randomized controlled clinical study of the short-term efficacy and safety of berberine combined with XELOX chemotherapy for advanced gastric cancer |
|
|
| Recruiting | N/A | 40 | | Berberine combined with XELOX ;XELOX | Tianjin Fourth Central Hospital; Tianjin Fourth Central Hospital, Self-financing. We intend to apply for the major special fund of Tianjin Public health science and technology. | gastric carcinoma | | | | |
OrganoHIPEC, NCT06057298: Patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases |
|
|
| Recruiting | N/A | 24 | Europe | Patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Peritoneal Metastases From Colorectal Cancer | 06/25 | 06/25 | | |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
NCT05354674: Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis |
|
|
| Not yet recruiting | N/A | 302 | RoW | Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 07/25 | 07/28 | | |
ChiCTR2100048333: Study on safety and efficacy of apatinib combined with SOX compared with SOX in postoperative adjuvant therapy for locally advanced gastric cancer (T3-4Nx +M0) |
|
|
| Not yet recruiting | N/A | 166 | | Tigerio + Oxaliplatin ;Tigerio + oxaliplatin + apatinib | Luwan Branch, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University; Luwan Branch, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, self-financed | Gastric cancer | | | | |
PROPERTY, NCT05025826: Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy |
|
|
| Recruiting | N/A | 110 | Europe | Phycocare, Placebo | Nantes University Hospital, Algosource | Metastatic Gastric Cancer | 08/25 | 03/26 | | |
NCT05496491: Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial |
|
|
| Recruiting | N/A | 84 | Europe | Neoadjuvant Chemoradiotherapy, nCRT, Adjuvant Chemotherapy, AC, Consolidation Chemotherapy, CC | Larissa University Hospital | Rectal Neoplasms | 08/25 | 08/25 | | |
ChiCTR2000037827: Single center, single arm, prospective and open clinical study of pyrroltinib maleate tablets and trastuzumab combined with FOLFOX6 regimen in the preoperative treatment of HER-2 positive colorectal cancer |
|
|
| Not yet recruiting | N/A | 30 | | pyrroltinib maleate tablets and trastuzumab combined with FOLFOX6 regimen | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-raised | HER-2 positive colorectal cancer | | | | |
NCT05978349: PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer |
|
|
| Recruiting | N/A | 150 | RoW | adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro, PTC drug sensitivity results | Peking Union Medical College Hospital | Colo-rectal Cancer | 09/25 | 09/25 | | |
ChiCTR2200061063: Clinical study of oxaliplatin plus raltitrexed hepatic arterial infusion chemotherapy (HAIC) combined with targeted drugs (sorafenib/lenvatinib/donafenib) in the treatment of unresectable patients with recurrent hepatocellular carcinoma after liver transplantation |
|
|
| Recruiting | N/A | 66 | | HAIC plus targeted therapy ;Only targeted therapy | The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of Sun Yat-Sen University, self-raised | Hepatocellular carcinoma | | | | |
NCT05718492: A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents |
|
|
| Recruiting | N/A | 100 | RoW | digital subtraction angiography., FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil ) | Sun Yat-sen University | Hepatocellular Carcinoma | 10/25 | 10/26 | | |
ChiCTR2000030600: Study on the safety and effectiveness of cytoreductive surgery for colorectal cancer peritoneal metastasis patients who are sensitive to the first-line chemotherapy of FOLFOXIRI combined with bevacizumab |
|
|
| Recruiting | N/A | 39 | | FOLFOXIRI, bevacizumab combined with cytoreductive surgery | The Sixth Affiliated Hospital, Sun Yat-Sen University; The Sixth Affiliated Hospital, Sun Yat-sen University, PI self-financing | synchronous peritoneal metastasis in colorectal cancer | | | | |
NCT05780684: Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer |
|
|
| Recruiting | N/A | 36 | US | FOX dose-escalation algorithm | Dartmouth-Hitchcock Medical Center | Colorectal Cancer, Esophagus Cancer, Appendix Cancer, Small Bowel Cancer, Ampullary Cancer | 11/25 | 05/26 | | |
ChiCTR2200065711: HAIC or Lenvatinib combined with Sintilimab as a neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma |
|
|
| Not yet recruiting | N/A | 60 | | Oxaliplatin 85 mg/m^2, formyltetrahydrofolic acid 400 mg/m^2, fluorouracil 400 mg/m^2, followed by a continuous infusion of fluorouracil 2400 mg/m^2 every 3 weeks for 46 hours, a total of 2 cycles ;Lenvatinib (12 or 8mg/kg, po, qd) in combination with Sindillizumab (200mg, iv, d1, q3w) | Tianjin Medical University Cancer Institute & Hospital; Tianjin Medical University Cancer Institute & Hospital, self-funded | hepatocellular carcinoma | | | | |
NCT05189171: MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer |
|
|
| Completed | N/A | 46 | US | MicroOrganoSphere (MOS) drug screen | Xilis, Inc. | Colorectal Neoplasms | 11/23 | 03/24 | | |
NCT05932836: An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC |
|
|
| Recruiting | N/A | 165 | RoW | No interventions. | Xiangya Hospital of Central South University | Hepatocellular Carcinoma | 12/25 | 02/26 | | |
OCEAN, NCT04416490: Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer |
|
|
| Recruiting | N/A | 2000 | RoW | | Boryung Pharmaceutical Co., Ltd | Stage II Colon Cancer, Stage III Colon Cancer | 03/26 | 03/26 | | |
| Not yet recruiting | N/A | 100 | NA | anlotinib+CAPEOX/SOX, anlotinib+chemotherapy | Xijing Hospital | Adjuvant Treatment | 07/26 | 07/29 | | |
ChiCTR2200062002: A Multicenter Clinical Trial of Neoadjuvant Therapy for Locally Advanced Rectal Cancer Based on Genotyping |
|
|
| Not yet recruiting | N/A | 100 | China | Tislelizumab 200mg ivdrop every 3 weeks for 4 cycles ;mFolfOx6 chemotherapy combined with EGFR monoclonal antibody and Tislelizumab ;Standard neoadjuvant chemoradiotherapy regimen combined with Tislelizumab | Tianjin Medical University General Hospital ; Tianjin Medical University General Hospital, Clinical trial research fund of Tianjin Medical University General Hospital | locally advanced rectal cancer，LARC | | | | |
ACUPOX, NCT05850130: Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients |
|
|
| Recruiting | N/A | 182 | Europe | Acupuncture intervention, No acupuncture | GERCOR - Multidisciplinary Oncology Cooperative Group | Colorectal Cancer, Liver Cancer, Gastric Cancer, Pancreas Cancer, Esophagus Cancer | 10/26 | 12/27 | | |
NCT06048146: A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis |
|
|
| Enrolling by invitation | N/A | 180 | RoW | Experimental: FOLFOXIRI and Lateral lymph node dissection, Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Lymph Node Metastasis, Cancer of Rectum and Anus, Oxaliplatin, Intestinal Neoplasms, Gastrointestinal Neoplasms, Rectal Diseases, Rectal Neoplasms | 09/27 | 09/29 | | |
ChiCTR2100050816: An observational study of apatinib combined with XELOX regimen in postoperative adjuvant therapy of colorectal cancer |
|
|
| Recruiting | N/A | 100 | | Apatinib combined with oxaliplatin and capecitabine (XELOX) g | The Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Self-funded | Colorectal cancer | | | | |
ChiCTR2300067545: A single-arm, multicenter, phase II study to evaluate the efficacy and safety of sequential treatment with chemotherapy and cadonilimab after preoperative short course radiotherapy for locally advanced rectal cancer |
|
|
| Not yet recruiting | N/A | 50 | | Short-course radiotherapy+AK104 injection+Oxaliplatin+Carbazitabine+TME surgery | Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Akeso Phamarceuticals,Inc. | Locally advanced rectal cancer | | | | |
GemSign-01, NCT06046794: Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients |
|
|
| Not yet recruiting | N/A | 100 | NA | Analyze of GemCore status | Institut Paoli-Calmettes | Cancer Of Pancreas | 11/27 | 11/27 | | |
NCT06122480: Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | N/A | 40 | US | Surgery | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease | 12/27 | 04/28 | | |
ADAPTA, NCT06068023: The Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. |
|
|
| Recruiting | N/A | 400 | Europe | Folfirinox, leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin., Capox, Capecitabine and oxaliplatin | Fondazione Poliambulanza Istituto Ospedaliero, Associazione Italiana per la Ricerca sul Cancro | Ampullary Adenocarcinoma | 07/28 | 07/29 | | |
| Recruiting | N/A | 93 | Europe | Total neoadjuvant therapy (TNT), Minimal residual disease (MRD), Long radiation therapy | Helsinki University Central Hospital | Colorectal Cancer | 08/28 | 12/31 | | |
ChiCTR2100046154: Clinical study of the efficacy and safety of Sintilimab combined with Oxaliplatin/S-1 (SOX) and radiotherapy in neoadjuvant therapy for locally advanced gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | N/A | 32 | | PD-1 inhibitor + SOX chemotharapy + radiotherapy | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-financing | Gastroesophageal junction tumor | | | | |
SHAPERS, NCT06052332: Efficacy and Safety of SCRT Versus TNT in Older Patients With Locally Advanced Rectal Cancer |
|
|
| Recruiting | N/A | 230 | Europe | Short course radiotherapy, Adjuvant chemotherapy (optional), Total mesorectal excision, Total neoadjuvant therapy | Jules Bordet Institute | Locally Advanced Rectal Cancer, Older People | 12/29 | 12/33 | | |
NCT05338866: Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator |
|
|
| Enrolling by invitation | N/A | 58 | RoW | Magnetic resonance guided radiotherapy, Chemotherapy, Capox, Capecitabine | Sun Yat-sen University | Rectal Cancer | 12/30 | 12/33 | | |
| Recruiting | N/A | 150 | Europe | BEP Protocol, Dose-dense protocol, Early surgery or high-dose chemotherapy, Dose-dense regimen, Early tumor resection or HD-CT | Gustave Roussy, Cancer Campus, Grand Paris, GUSTAVE ROUSSY | Non-Seminomatous Germ Cell Tumor | 02/31 | 02/37 | | |
ACTRN12617001571369: Stereotactic ablative body radiotherapy for Unresectable Pancreatic cancer with Endoscopic ultrasound inserted fiducial markers and concuRrent chemotherapy (SUPER) trial. |
|
|
| Not yet recruiting | N/A | 250 | | | Royal Adelaide Hospital, Royal Adelaide Hospital | Pancreatic cancer tumours | | | | |
ACTRN12622000180718: Survival and Patterns of Care in the Era of Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT)-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (SPACE-FLOT):
An international multicentre cohort study |
|
|
| Not yet recruiting | N/A | 1575 | | | Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre | Gastroesophageal adenocarcinomas, Gastroesophageal cancer, Gastric cancer, Gastric adenocarcinomas | | | | |
ACTRN12606000354583: The Effects of Neoadjuvant Chemotherapy for Colorectal Liver Metastases on Functional Hepatic Reserves as Assessed by Indocyanine Green Clearance - A Pilot Study. |
|
|
| Recruiting | N/A | 40 | | | Professor Guy J Maddern, The Department of Surgery Departmental Funding | Colorectal Liver Metastases | | | | |
ACTRN12618001017213: The Safety And Feasibility of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) in the treatment of Unresectable Disseminated Peritoneal Malignancy |
|
|
| Recruiting | N/A | 112 | | | Department of Surgery, University of Adelaide, TQEH, Department of Surgery, University of Adelaide, TQEH | Peritoneal Metastases | | | | |
ACTRN12608000403336: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer |
|
|
| Active, not recruiting | N/A | 1090 | | | Australasian Gastro-Intestinal Trials Group (AGITG), Cancer Australia | Rectal cancer, Locally Advanced Rectal Cancer | | | | |